肉瘤挑战会议（CCS） 2024：非循证管理方面的专家意见

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-03-17 DOI:10.1016/j.ejca.2025.115368

Silvia Hofer , Chantal Pauli , Beata Bode , Sylvie Bonvalot , Christina Fotopoulou , Hans Gelderblom , Rick L Haas , Jendrik Hardes , Peter Hohenberger , Jens Jakob , Wolfgang G Kunz , Andreas Leithner , Bernadette Liegl-Atzwanger , Lars H Lindner , Aisha B Miah , Peter Reichardt , Piotr Rutkowski , Benedikt M Schaarschmidt , Katrin Scheinemann , Joanna Szkandera , Christian Rothermundt

{"title":"肉瘤挑战会议（CCS） 2024：非循证管理方面的专家意见","authors":"Silvia Hofer , Chantal Pauli , Beata Bode , Sylvie Bonvalot , Christina Fotopoulou , Hans Gelderblom , Rick L Haas , Jendrik Hardes , Peter Hohenberger , Jens Jakob , Wolfgang G Kunz , Andreas Leithner , Bernadette Liegl-Atzwanger , Lars H Lindner , Aisha B Miah , Peter Reichardt , Piotr Rutkowski , Benedikt M Schaarschmidt , Katrin Scheinemann , Joanna Szkandera , Christian Rothermundt","doi":"10.1016/j.ejca.2025.115368","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Soft tissue sarcomas (STS) and other mesenchymal tumours belong to rare, heterogeneous neoplasms with over 150 subtypes that pose significant challenges in diagnosis and clinical decision making. While guidelines address evidence-based diagnostic and therapeutic procedures, clinical situations and scenarios without evidence remain controversial in daily practice. The 2024 Conference on Challenges in Sarcoma (CCS2024) aimed to narrow these gaps with the support of an international and multidisciplinary panel of sarcoma experts.</div></div><div><h3>Methods</h3><div>A Delphi process identified 200 controversial questions across eight prioritised clinical scenarios, including tenosynovial giant cell tumour, synovial sarcoma of the extremities, retroperitoneal sarcomas, angiosarcoma, phyllodes tumour, malignant peripheral nerve sheath tumour, uterine leiomyosarcoma, and atypical lipomatous tumour.</div></div><div><h3>Results</h3><div>Sixty-four experts discussed 141 controversies during the conference and reached strong consensus (> 90 %) on 24 and consensus (> 75 %) on 45 key diagnostic and therapeutic issues, while unresolved controversies emphasized the need for further research.</div></div><div><h3>Conclusions</h3><div>CCS2024 provides a framework for clinical decision making and underscores the importance of consensus-driven approaches in the treatment of rare and complex malignancies.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115368"},"PeriodicalIF":7.6000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects\",\"authors\":\"Silvia Hofer , Chantal Pauli , Beata Bode , Sylvie Bonvalot , Christina Fotopoulou , Hans Gelderblom , Rick L Haas , Jendrik Hardes , Peter Hohenberger , Jens Jakob , Wolfgang G Kunz , Andreas Leithner , Bernadette Liegl-Atzwanger , Lars H Lindner , Aisha B Miah , Peter Reichardt , Piotr Rutkowski , Benedikt M Schaarschmidt , Katrin Scheinemann , Joanna Szkandera , Christian Rothermundt\",\"doi\":\"10.1016/j.ejca.2025.115368\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Soft tissue sarcomas (STS) and other mesenchymal tumours belong to rare, heterogeneous neoplasms with over 150 subtypes that pose significant challenges in diagnosis and clinical decision making. While guidelines address evidence-based diagnostic and therapeutic procedures, clinical situations and scenarios without evidence remain controversial in daily practice. The 2024 Conference on Challenges in Sarcoma (CCS2024) aimed to narrow these gaps with the support of an international and multidisciplinary panel of sarcoma experts.</div></div><div><h3>Methods</h3><div>A Delphi process identified 200 controversial questions across eight prioritised clinical scenarios, including tenosynovial giant cell tumour, synovial sarcoma of the extremities, retroperitoneal sarcomas, angiosarcoma, phyllodes tumour, malignant peripheral nerve sheath tumour, uterine leiomyosarcoma, and atypical lipomatous tumour.</div></div><div><h3>Results</h3><div>Sixty-four experts discussed 141 controversies during the conference and reached strong consensus (> 90 %) on 24 and consensus (> 75 %) on 45 key diagnostic and therapeutic issues, while unresolved controversies emphasized the need for further research.</div></div><div><h3>Conclusions</h3><div>CCS2024 provides a framework for clinical decision making and underscores the importance of consensus-driven approaches in the treatment of rare and complex malignancies.</div></div>\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"220 \",\"pages\":\"Article 115368\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804925001492\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925001492","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：软组织肉瘤（STS）和其他间充质肿瘤属于罕见的异质性肿瘤，有超过150种亚型，在诊断和临床决策方面提出了重大挑战。虽然指南涉及循证诊断和治疗程序，但在日常实践中，没有证据的临床情况和情景仍然存在争议。在国际多学科肉瘤专家小组的支持下，2024年肉瘤挑战会议（CCS2024）旨在缩小这些差距。方法采用德尔菲法（Delphi process）对8种临床表现（包括腱鞘巨细胞瘤、四肢滑膜肉瘤、腹膜后肉瘤、血管肉瘤、叶状瘤、周围神经鞘恶性肿瘤、子宫平滑肌肉瘤和非典型脂肪瘤肿瘤）的200个争议性问题进行筛选。结果64位专家在会议期间讨论了141项争议，达成了强烈共识(>；90 %)和共识(>；75 %)在45个关键的诊断和治疗问题上，而未解决的争议强调了进一步研究的必要性。结论sccs2024为临床决策提供了一个框架，并强调了共识驱动方法在治疗罕见和复杂恶性肿瘤中的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects

Background

Soft tissue sarcomas (STS) and other mesenchymal tumours belong to rare, heterogeneous neoplasms with over 150 subtypes that pose significant challenges in diagnosis and clinical decision making. While guidelines address evidence-based diagnostic and therapeutic procedures, clinical situations and scenarios without evidence remain controversial in daily practice. The 2024 Conference on Challenges in Sarcoma (CCS2024) aimed to narrow these gaps with the support of an international and multidisciplinary panel of sarcoma experts.

Methods

A Delphi process identified 200 controversial questions across eight prioritised clinical scenarios, including tenosynovial giant cell tumour, synovial sarcoma of the extremities, retroperitoneal sarcomas, angiosarcoma, phyllodes tumour, malignant peripheral nerve sheath tumour, uterine leiomyosarcoma, and atypical lipomatous tumour.

Results

Sixty-four experts discussed 141 controversies during the conference and reached strong consensus (> 90 %) on 24 and consensus (> 75 %) on 45 key diagnostic and therapeutic issues, while unresolved controversies emphasized the need for further research.

Conclusions

CCS2024 provides a framework for clinical decision making and underscores the importance of consensus-driven approaches in the treatment of rare and complex malignancies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.